CHA Biotech

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • USD 10% exchange rate move → ±KRW 356M impact on profit for FY2025, similar to ±KRW 372M prior year
• • Financial liabilities contractually due within 1 year KRW 1.35T in FY2025, up from KRW 1.04T in prior year

Management Discussion & Analysis

• • Revenue KRW 1.2683T (+21.36% YoY); Operating loss KRW 48.8B (loss narrowed by KRW 10.9B); Net loss KRW 150.8B (+1202.93%)
• • Hospital sales contributed KRW 743.9B (+16.57%), driven by US Hollywood hospital and Australian IVF service expansion

Business Overview

• • Revenue mix FY2025: medical services 58.65%, products (pharmaceutical, cosmetics) 9.61%, global CDMO and others 31.74%
• • Signed license-out agreement Mar 2023 with Astellas Institute of Regenerative Medicine for RPE and Blastomere tech, total contract KRW 42.2B

What are the latest CHA Biotech DART filings in 2026?

CHA Biotech (KRX code 085660) has filed an annual report on March 31, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did CHA Biotech file its most recent annual report?

CHA Biotech filed its most recent annual report on March 31, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is CHA Biotech's KRX stock code?

CHA Biotech's KRX stock code is 085660. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 085660 to look up all CHA Biotech disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does CHA Biotech file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for CHA Biotech.

Where can I find CHA Biotech financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from CHA Biotech annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.